Table 3 Univariate Cox proportional hazards regression analysis for overall survival and relapse-free survival in non-invasive high-grade and invasive bladder urothelial carcinomas
Characteristics | OS | RFS | ||
|---|---|---|---|---|
HR (95% CI) | p | HR (95% CI) | p | |
Sex, female (vs. male) | 1.014 (0.503–2.042) | 0.969 | 1.065 (0.532–2.134) | 0.859 |
Age, y ≥ 65 (vs. < 65) | 1.776 (0.953–3.309) | 0.055 | 1.265 (0.738–2.167) | 0.392 |
Grade, high (vs. low) | 2.924 (1.398–6.117) | 0.004 | 2.547 (1.307–4.963) | 0.006 |
T stage, Ta | 1 |  < 0.001 | 1 | 0.012 |
 T1 | 1.372 (0.419–4.497) | 0.601 | 0.916 (0.361–2.323) | 0.854 |
 T2–4 | 5.054 (1.55–16.475) | 0.007 | 1.842 (0.717–4.729) | 0.204 |
N stage, N1-3 (vs. N0) | 5.832 (2.575–13.211) |  < 0.001 | 3.087 (1.319–7.227) | 0.009 |
M stage, M1 (vs. M0) | 7.814 (3.038–20.096) |  < 0.001 | 0.894 (0.123–6.48) | 0.912 |
TNM stage, Stage 0 | 1 |  < 0.001 | 1 | 0.027 |
 Stage I | 1.374 (0.419–4.503) | 0.6 | 0.916 (0.362–2.323) | 0.916 |
 Stage II, III | 4.625 (1.41–15.177) | 0.012 | 1.88 (0.731–4.835) | 0.19 |
 Stage IV | 17.793 (4.119–76.872) |  < 0.001 | 1.085 (0.126–9.368) | 0.879 |
FAM83H, positive (vs. negative) | 3.423 (1.748–6.704) |  < 0.001 | 3.83 (2.06–7.121) |  < 0.001 |
Nectin1, positive (vs. negative) | 2.48 (1.415–4.346) | 0.002 | 2.475 (1.469–4.169) | 0.001 |
Combined expression, FAM83H−/Nectin1− | 1 | 0.001 | 1 |  < 0.001 |
 FAM83H−/Nectin1+ or FAM83H+/Nectin1− | 3.89 (1.424–10.624) | 0.008 | 3.36 (1.392–8.11) | 0.007 |
 FAM83H+/Nectin1+ | 5.579 (2.216–14.046) |  < 0.001 | 5.309 (2.402–11.735) |  < 0.001 |